Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents (Grand-DES)

April 22, 2026 updated by: Hyo-Soo Kim, Seoul National University Hospital

The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use of DES in the real world.

The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The Grand Drug-Eluting Stent (Grand-DES) Registry incorporated five different multicenter registries in South Korea. The EXCELLENT prospective cohort and the EXCELLENT-PRIME registry were dedicated for durable polymer-coated everolimus-eluting stents (DP-EES; Xience V/Promus and Xience Prime) or 1st-generation sirolimus-eluting stents (Cypher), the HOST-RESOLINTE and RESOLUTE-Korea registry for durable polymer-coated zotarolimus-eluting stents (DP-ZES; Resolute Integrity and Endeavor Resolute) or 1st-generation Endeavor-ZES, and the HOST-BIOLIMUS-3000-Korea registry for biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, and Nobori). During the period of 2008 through 2014, all registries enrolled all-comers without any exclusion criteria except patient's withdrawal of consent.

Study Type

Observational

Enrollment (Actual)

17286

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • South Korea
      • Anyang, South Korea
        • Hallym University Sacred Heart Hospital
      • Busan, South Korea
        • Kosin University Gospel Hospital
      • Cheonan, South Korea
        • Soon Chun Hyang University Hospital Cheonan
      • Cheonan, South Korea
        • Dankook University Hospital
      • Daejeon, South Korea
        • Chungnam National University Hospital
      • Gwangju, South Korea
        • Chonnam National University Hospital
      • Gwangju, South Korea
        • Gwangju Christian Hospital
      • Gwangju, South Korea
        • Kwangju Veterans Hospital
      • Iksan, South Korea
        • Wonkwang University Hospital
      • Iksan, South Korea
        • Chonbuk National University Hospital
      • Ilsan, South Korea
        • Inje University Ilsan Paik Hospital
      • Ilsan, South Korea
        • National Health Insurance Corporation Ilsan Hospital
      • Inchon, South Korea
        • Inha University Hospital
      • Jeonju, South Korea
        • Presbyterian Medical Center
      • Jeonju, South Korea
        • Chungbuk National University Hospital
      • Jinju, South Korea
        • Gyeongsang National University Hospital
      • Pusan, South Korea
        • Inje University Pusan Paik Hospital
      • Pusan, South Korea
        • Pusan National University Hospital
      • Seongnam, South Korea
        • Seoul National University Bundang Hospital
      • Seongnam, South Korea
        • Bundang CHA Medical Center
      • Seoul, South Korea
        • Korea University Guro Hospital
      • Seoul, South Korea
        • Samsung Medical Center
      • Seoul, South Korea
        • Gangnam Severance Hospital
      • Seoul, South Korea
        • Kyung Hee University Medical Center
      • Seoul, South Korea
        • Hanyang University Medical Center
      • Seoul, South Korea
        • Seoul Boramae Hospital
      • Seoul, South Korea
        • Kyung Hee University Hospital at Gangdong
      • Seoul, South Korea
        • Yonsei University Medical Center
      • Seoul, South Korea
        • Soonchunhyang University Hospital
      • Seoul, South Korea
        • Ewha Womans University Medical Center Mokdong Hospital
      • Seoul, South Korea
        • Gangbuk Samsung Hospital
      • Seoul, South Korea
        • Hallym University Kangdong Sacred Heart Hospital
      • Suncheon, South Korea
        • St. Carollo Hospital
      • Uijeongbu-si, South Korea
        • Uijeongbu St. Mary's Hospital
    • Gangwon-do
      • Wŏnju, Gangwon-do, South Korea
        • Wonju Severance Christian Hospital
    • Gyeonggi-do
      • Bucheon-si, Gyeonggi-do, South Korea
        • Sejong General Hospital
    • Jongno-gu
      • Seoul, Jongno-gu, South Korea, 03080
        • Seoul National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

A total of 17,286 patients derived from a population of patients receiving percutaneous coronary intervention for ischemic heart disease will be enrolled in the present registry.

Description

Inclusion Criteria:

  • The patient agrees to participate in this study by signing the informed consent form.
  • Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion Criteria:

  • There are no exclusion criteria for this registry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HOST-BIOLIMUS-Korea-3000
Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
Device: Biomatrix; Biomatrix Flex; Nobori
Biodegradable polymer-coated biolimus-eluting stents
Other Names:
  • BP-BES
EXCELLENT-PRIME
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
Device: Xience Prime
Durable polymer-coated everolimus-eluting stents
Other Names:
  • DP-EES-Prime
EXCELLENT Prospective cohort
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
Device: Xience V/Promus; Cypher
Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
Other Names:
  • DP-EES; SES
HOST-RESOLINTE
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
Device: DP-ZES-RI
Durable polymer-coated zotarolimus-eluting stents
Other Names:
  • Resolute Integrity
RESOLUTE-Korea
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
Device: Endeavor; Resolute
Durable polymer-coated zotarolimus-eluting stents
Other Names:
  • DP-ZES

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Target lesion failure
Time Frame: 36 months
A composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization
36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-oriented composite outcome
Time Frame: 36 months
A composite of all-cause death, all-cause myocardial infarction, and any repeat revascularization
36 months
All-cause death
Time Frame: 36 months
All-cause death
36 months
Cardiac death
Time Frame: 36 months
Cardiac death
36 months
All-cause myocardial infarction
Time Frame: 36 months
All-cause myocardial infarction
36 months
Target-vessel myocardial infarction
Time Frame: 36 months
Target-vessel myocardial infarction
36 months
Any repeat revascularization
Time Frame: 36 months
Any repeat revascularization
36 months
Clinically-driven target vessel revascularization
Time Frame: 36 months
Clinically-driven target vessel revascularization
36 months
Clinically-driven target lesion revascularization
Time Frame: 36 months
Clinically-driven target lesion revascularization
36 months
Definite or probable stent thrombosis
Time Frame: 36 months
Definite or probable stent thrombosis
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Investigators

  • Study Chair: Hyo-Soo Kim, MD, PhD, Seoul National University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2008

Primary Completion (Actual)

November 1, 2017

Study Completion (Actual)

November 30, 2017

Study Registration Dates

First Submitted

April 15, 2018

First Submitted That Met QC Criteria

April 15, 2018

First Posted (Actual)

April 24, 2018

Study Record Updates

Last Update Posted (Actual)

April 27, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Grand-DES

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Biomatrix; Biomatrix Flex; Nobori

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe